• bsi-innovation
  • bsi-learning
  • bsi-people
  • bsi-wealth

Hatchtech provides significant exit for Australian VCs

Blue sky, Oneventures, Uniseed, FBs Ventures and QIC has just had an exit with biotech startup Hatchtech, securing a deal worth $280m

Hatchtech is a biotech focusing on the treatment of HeadLice.The technology company offers the only treatment effective in killing both hatched lice and their eggs in a single treatment.

Elaine Stead of Bluesky says that the investors worked well to add value to the startup. 

Hatchtech has reached a commercial agreement with Indian-based Dr Reddy’s Laboratories for upfront and pre-commercialisation payments of $84 million and commercial milestone payments of $193 million.

Blue Sky invested in the Melbourne-based health-tech company in 2013 as part of a $12 million syndicate led by OneVentures.

“The company executed its strategy perfectly and this is precisely in line with the investment thesis,” she says.

it’s a great result for investors, and for the Australian venture capital sector.

“It’s an excellent example of what can be achieved with world class research, innovation and management teams and collaborative venture investors.” 

Posted on September 27, 2015

One response to “Hatchtech provides significant exit for Australian VCs”

  1. Nice post. I have bookmarked you to check your new stuff.

    venture capital firms

Leave a Reply

Your email address will not be published. Required fields are marked *


Contact us today to find out how we can make your business grow!
Ph: 02 9126 9100  Email: info@bsi.com.au
Level 9, Angel Place,123 Pitt Street
Sydney NSW 2000

© Copyright 2024 BSI